Related Experiment Video
Updated: Jan 14, 2026
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With
Joo-Hwan Park1, Hee Kyung Ahn1,2, Hye Ryun Kim3
1Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, Republic of Korea.
Background:
HPV-negative HNSCC is driven by cell cycle dysregulation, including CDK4/6 activation. Abemaciclib targets this pathway and may offer therapeutic benefits. This study aimed to identify biomarkers predicting abemaciclib efficacy.
Methods:
In the NGS-based TRIUMPH trial, patients with platinum-refractory HNSCC harboring CDK4/6 pathway alteration received abemaciclib, classified as "long stable disease (SD)" (progression-free survival [PFS] > 6 months) and "short SD" (PFS < 6 months). In this post hoc analysis, the genetic profiles were compared. In vitro studies were conducted to assess abemaciclib's antitumor effects in HNSCC cell lines.
Results:
Among 23 patients, abemaciclib showed limited efficacy (overall response rate, 0%; disease control rate, 43.5%). CDKN2A deletion was significantly associated with long SD (p = 0.0078), unlike CCND1 amplification and CDKN2A mutation. In vitro, CDKN2A-deleted cell lines showed greater sensitivity to abemaciclib.
Conclusions:
Although abemaciclib resulted in limited tumor regression, CDKN2A deletion may be a predictive biomarker for prolonged disease stabilization. Further investigations on genomically selected populations and combination strategies are required.
Insights
In HPV-negative head and neck squamous cell carcinoma (HNSCC), CDKN2A deletion may predict longer disease stabilization with abemaciclib, despite limited overall efficacy. Further research is needed.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- HPV-negative head and neck squamous cell carcinoma (HNSCC) is characterized by cell cycle dysregulation, particularly CDK4/6 pathway activation.
- Abemaciclib, a CDK4/6 inhibitor, is a potential therapeutic agent for this patient population.
Purpose of the Study:
- To identify biomarkers that predict the efficacy of abemaciclib in patients with platinum-refractory HNSCC.
- To evaluate the association between genetic alterations and clinical outcomes in patients treated with abemaciclib.
Main Methods:
- A post hoc analysis of the TRIUMPH trial (NGS-based) compared genetic profiles of patients with long stable disease (SD; progression-free survival [PFS] > 6 months) versus short SD (PFS < 6 months).
- In vitro studies assessed abemaciclib's antitumor effects on HNSCC cell lines.
Main Results:
- Abemaciclib demonstrated limited efficacy in 23 patients, with a 0% overall response rate and 43.5% disease control rate.
- CDKN2A deletion was significantly associated with longer SD (p=0.0078), whereas CCND1 amplification and CDKN2A mutation were not.
- In vitro, HNSCC cell lines with CDKN2A deletion exhibited increased sensitivity to abemaciclib.
Conclusions:
- CDKN2A deletion may serve as a predictive biomarker for prolonged disease stabilization in response to abemaciclib in HNSCC.
- Further investigation is warranted in genomically selected populations and combination therapy strategies.
More Related Videos
07:03Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
